Reviva Pharmaceuticals Files 8-K
Ticker: RVPH · Form: 8-K · Filed: May 30, 2025
Sentiment: neutral
Topics: material-agreement, financials, filing
TL;DR
Reviva Pharma dropped an 8-K on 5/30 - looks like a material agreement and financials.
AI Summary
Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on May 30, 2025, reporting the entry into a material definitive agreement and filing financial statements and exhibits. The company, formerly Tenzing Acquisition Corp., is incorporated in Delaware and operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing indicates a significant event for Reviva Pharmaceuticals, potentially related to new agreements or financial disclosures that could impact investors.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can lead to price volatility, but the specific nature of the agreement is not detailed here.
Key Numbers
- 001-38634 — SEC File Number (Identifies the company's filing history with the SEC.)
- 85-4306526 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- REVIVA PHARMACEUTICALS HOLDINGS, INC. (company) — Registrant
- Tenzing Acquisition Corp. (company) — Former company name
- May 30, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 10080 N. Wolfe Rd. , Suite SW3-200 Cupertino , CA 95014 (address) — Principal executive offices
FAQ
What is the specific nature of the material definitive agreement entered into by Reviva Pharmaceuticals?
The filing does not specify the details of the material definitive agreement, only that one was entered into.
What are the key financial statements and exhibits being filed with this 8-K?
The filing indicates that financial statements and exhibits are being filed, but their specific content is not detailed in the provided text.
When did Reviva Pharmaceuticals Holdings, Inc. change its name from Tenzing Acquisition Corp.?
The date of the name change from Tenzing Acquisition Corp. to Reviva Pharmaceuticals Holdings, Inc. was June 6, 2018.
What is Reviva Pharmaceuticals Holdings, Inc.'s primary industry?
Reviva Pharmaceuticals Holdings, Inc. operates in the Pharmaceutical Preparations industry, with SIC code 2834.
Where are Reviva Pharmaceuticals Holdings, Inc.'s principal executive offices located?
The principal executive offices are located at 10080 N. Wolfe Rd., Suite SW3-200, Cupertino, CA 95014.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 30, 2025 regarding REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH).